When does this change take effect?

This change is effective Mar 4, 2026.

Back to dashboard

CommercialCoverageLow impact

06.02.38d, Nerve Fiber Density Testing

Q: Who is affected by this change?

This affects Independence Blue Cross Neurology, Endocrinology, Pain Management providers on Commercial plans.

Independence Blue Cross·Neurology, Endocrinology, Pain Management·Medical Policy

Effective date

Mar 4, 2026

We identified it

Jun 19, 2026

Days to comply

—

Summary

IBX has reissued their nerve fiber density testing policy (06.02.38d) for commercial plans. This appears to be a policy reissue without substantive changes to existing coverage guidelines.

Action Required

Action needed

By March 4, 2026: Review updated nerve fiber density testing policy 06.02.38d on IBX provider portal to identify any changes in coverage criteria or documentation requirements for commercial members.

Related policy hubs

Independence Blue Cross policies Neurology Endocrinology Pain Management